Works matching DE "SUNITINIB"
Results: 258
Bevacizumab and sunitinib mediate osteogenic and pro-inflammatory molecular changes in primary human alveolar osteoblasts in vitro.
- Published in:
- Odontology, 2022, v. 110, n. 4, p. 634, doi. 10.1007/s10266-022-00691-y
- By:
- Publication type:
- Article
Synthetic pathways to 5-fluoroindolin-2-one: key intermediate for sunitinib.
- Published in:
- Chemistry of Heterocyclic Compounds, 2024, v. 60, n. 9, p. 422, doi. 10.1007/s10593-024-03356-6
- By:
- Publication type:
- Article
Molecular characterization, clinical value, and cancer–immune interactions of genes related to disulfidptosis and ferroptosis in colorectal cancer.
- Published in:
- Discover Oncology, 2024, v. 15, n. 1, p. 1, doi. 10.1007/s12672-024-01031-y
- By:
- Publication type:
- Article
PDIA4 在肾癌细胞舒尼替尼耐药中的作用研究.
- Published in:
- Progress in Modern Biomedicine, 2024, v. 24, n. 13, p. 2408, doi. 10.13241/j.cnki.pmb.2024.13.002
- By:
- Publication type:
- Article
Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-56335-4
- By:
- Publication type:
- Article
Apela promotes blood vessel regeneration and remodeling in zebrafish.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-023-50677-1
- By:
- Publication type:
- Article
Pharmacokinetics and bioequivalence of sunitinib and Sutent® in Chinese healthy subjects: an open-label, randomized, crossover study.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1294688
- By:
- Publication type:
- Article
Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1223929
- By:
- Publication type:
- Article
Preparation of a Sunitinib loaded microemulsion for ocular delivery and evaluation for the treatment of corneal neovascularization in vitro and in vivo.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1157084
- By:
- Publication type:
- Article
Psychiatric adverse reactions to non-selective RET multi-kinase inhibitors: a large-scale pharmacovigilance analysis.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1209933
- By:
- Publication type:
- Article
Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1122885
- By:
- Publication type:
- Article
Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-39981-6
- By:
- Publication type:
- Article
Exploration of the immune microenvironment of breast cancer in large population cohorts.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.955630
- By:
- Publication type:
- Article
Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study.
- Published in:
- Clinical Genitourinary Cancer, 2021, v. 19, n. 4, p. 354, doi. 10.1016/j.clgc.2021.03.006
- By:
- Publication type:
- Article
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Clinical Genitourinary Cancer, 2021, v. 19, n. 1, p. 22, doi. 10.1016/j.clgc.2020.05.013
- By:
- Publication type:
- Article
AVAPRITINIB U ČETVRTOJ LINIJI LIJEČENJA METASTATSKOG GASTROINTESTINALNOG STROMALNOG TUMORA – PRIKAZ SLUČAJA.
- Published in:
- Lijecnicki Vjesnik, 2024, v. 146, p. 8, doi. 10.26800/LV-146-supl4-1
- By:
- Publication type:
- Article
Prognostic model for overall survival that includes the combination of platelet count and neutrophil-lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma.
- Published in:
- 2022
- By:
- Publication type:
- journal article
A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor.
- Published in:
- BMC Cancer, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12885-022-09610-4
- By:
- Publication type:
- Article
Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 94, n. 2, p. 297, doi. 10.1007/s00280-024-04678-0
- By:
- Publication type:
- Article
Are novel oral oncolytics underdosed in obese patients?
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 2, p. 129, doi. 10.1007/s00280-023-04601-z
- By:
- Publication type:
- Article
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 2, p. 179, doi. 10.1007/s00280-022-04500-9
- By:
- Publication type:
- Article
Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 6, p. 751, doi. 10.1007/s00280-022-04432-4
- By:
- Publication type:
- Article
Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Hsa_circ_0072732 enhances sunitinib resistance of renal cell carcinoma by inhibiting ferroptosis.
- Published in:
- Discover Oncology, 2024, v. 15, n. 1, p. 1, doi. 10.1007/s12672-024-01580-2
- By:
- Publication type:
- Article
DFT Conformational, Wavefunction Based Reactivity Analysis, Docking and MD Simulations of a Carboxamide Derivative with Potential Anticancer Activity.
- Published in:
- Polycyclic Aromatic Compounds, 2023, v. 43, n. 2, p. 1590, doi. 10.1080/10406638.2022.2032765
- By:
- Publication type:
- Article
Unveiling the Anti-Angiogenic Potential of Small-Molecule (Kinase) Inhibitors for Application in Rheumatoid Arthritis.
- Published in:
- Cells (2073-4409), 2025, v. 14, n. 2, p. 102, doi. 10.3390/cells14020102
- By:
- Publication type:
- Article
Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma.
- Published in:
- BJU International, 2024, v. 134, n. 4, p. 596, doi. 10.1111/bju.16403
- By:
- Publication type:
- Article
Dynamic biomarker and imaging changes from a phase II study of pre‐ and post‐surgical sunitinib.
- Published in:
- BJU International, 2022, v. 130, n. 2, p. 244, doi. 10.1111/bju.15600
- By:
- Publication type:
- Article
Cytoreductive nephrectomy and exposure to sunitinib – a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial.
- Published in:
- BJU International, 2022, v. 130, n. 1, p. 68, doi. 10.1111/bju.15625
- By:
- Publication type:
- Article
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group‐American College of Radiology Imaging Network (ECOG‐ACRIN) E2805.
- Published in:
- BJU International, 2022, v. 129, n. 6, p. 718, doi. 10.1111/bju.15587
- By:
- Publication type:
- Article
Regorafenib-related erythrocytosis in metastatic extra-gastrointestinal stromal tumor: a case report.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1398055
- By:
- Publication type:
- Article
Sunitinib for adenocarcinoma of the rete testis: a case report.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1358133
- By:
- Publication type:
- Article
Case report: Isolated eyelid metastasis of ccRCC 5 years after receiving radical nephrectomy.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1321919
- By:
- Publication type:
- Article
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1343027
- By:
- Publication type:
- Article
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1223282
- By:
- Publication type:
- Article
Corrigendum: Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1376408
- Publication type:
- Article
Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity scorematched cohorts of cancer of unknown primary treatment.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1191611
- By:
- Publication type:
- Article
PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1343004
- By:
- Publication type:
- Article
Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1325999
- By:
- Publication type:
- Article
Case Report: A novel TP53 mutation in a patient with quadruple wild-type gastrointestinal stromal tumor.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1260706
- By:
- Publication type:
- Article
Corrigendum: Long non-coding RNA CCAT1 acts as an oncogene and promotes sunitinib resistance in renal cell carcinoma.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1247057
- Publication type:
- Article
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
- Published in:
- Frontiers in Oncology, 2023, p. 01, doi. 10.3389/fonc.2023.1223282
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitor Combined with Antiangiogenic Agent Synergistically Improving the Treatment Efficacy for Solid Tumors.
- Published in:
- ImmunoTargets & Therapy, 2024, v. 13, p. 813, doi. 10.2147/ITT.S494670
- By:
- Publication type:
- Article
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy: Traditional Versus Pharmacometric Pharmacoeconomic Models for Cost-Utility Analysis of Sunitinib: M. Centanni et al
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 1, p. 31, doi. 10.1007/s40273-024-01438-z
- By:
- Publication type:
- Article
Supplementary Materials.
- Published in:
- Frontiers in Endocrinology, 2024, p. 1
- Publication type:
- Article
Sunitinib Reduced the Migration of Ectopic Endometrial Cells via p-VEGFR-PI3K-AKT-YBX1-Snail Signaling Pathway.
- Published in:
- Analytical Cellular Pathology: Cellular Oncology, 2022, p. 1, doi. 10.1155/2022/6042518
- By:
- Publication type:
- Article
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
- Published in:
- PLoS ONE, 2023, v. 17, n. 4, p. 1, doi. 10.1371/journal.pone.0279786
- By:
- Publication type:
- Article
Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial.
- Published in:
- Cancer (0008543X), 2025, v. 131, n. 1, p. 1, doi. 10.1002/cncr.35628
- By:
- Publication type:
- Article
Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510).
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 22, p. 3836, doi. 10.1002/cncr.35483
- By:
- Publication type:
- Article